Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma

Onkologie

Volumn 29, Issue 12, 2006, Pages 572-574

  Hof, H ^a,b   Welzel, T ^a   Debus, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cetuximab; Chordoma; Epidermal growth factor; Gefitinib; Lung metastases

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHORDOMA; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG METASTASIS; MALE; PROTEIN EXPRESSION; SACRAL SPINAL CORD; SKIN DEFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORDOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; SACRUM; SPINAL NEOPLASMS; TREATMENT OUTCOME;

EID: 33845787013     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096283     Document Type: Article

References (9)

1. Unusual nonepithelial tumors of the head and neck; in Chao C, Perez C, Brady L (eds): Radiation Oncology: Management Decisions. Philadelphia, PA Lippincott Raven, 1999, pp 275-296.
2. Rich TA, Schiller A, Suit HD, Mankin HJ: Clinical and pathologic review of 48 cases of chordoma. Cancer 1985;56:182-7.
3. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
5. Macarulla T, Casado E, Ramos FJ, Valverde C, Tabernero J: Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer. Onkologie 2006;29:99-105.
6. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
9. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.